Soybean agglutinin-conjugated silver nanoparticles nanocarriers in the treatment of breast cancer cells

Rocio Guadalupe Casañas Pimentel, Viviana Robles Botero, Eduardo San Martín Martínez, Consuelo Gómez García, Juan Paulo Hinestroza

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

© 2016 Taylor & Francis. Silver nanoparticles (AgNPs) induce diverse cell-death mechanisms, similar to those promoted by anticancer chemotherapeutics; however, they have not been tested in vivo because their action is not limited to cancer cells. Therefore, in vivo evaluations of their effectiveness should be developed with targeting systems. Breast cancer shows changes in the sugar expression patterns on cell surfaces, related to cancer progression and metastases; those changes have been identified previously by the specific binding of soybean agglutinin (SBA). Here is proposed the use of SBA to target the AgNP activity in breast cancer. For that, the present work reports the synthesis of AgNPs (3.89 ± 0.90 nm) through the polyol method, the generation of AgNP nanocarriers, and the bioconjugation protocol of the nanocarrier with SBA. The free AgNPs, the AgNP nanocarriers, and the SBA-bioconjugated AgNP nanocarriers were tested for cytotoxicity in breast cancerous (MDA-MB-231and MCF7) and non cancerous (MCF 10A) cells, using the MTT assay. AgNPs demonstrated cytotoxic activity in vitro, the non cancerous cells (MCF 10A) being more sensible than the cancerous cells (MDA-MB-231 and MCF7) showing LD50 values of 128, 205, and 319 M Ag, respectively; the nanoencapsulation decreased the cytotoxic effect of AgNPs in non cancerous cells, maintaining or increasing the effect on the cancer-derived cells, whereas the SBA-bioconjugation allowed AgNP cytotoxic activity with a similar behavior to the nanocarriers. Future experiments need to be developed to evaluate the targeting effect of the SBA-bioconjugated AgNP nanocarriers to study their functionality in vivo.
Original languageAmerican English
Pages (from-to)218-234
Number of pages194
JournalJournal of Biomaterials Science, Polymer Edition
DOIs
StatePublished - 11 Feb 2016

Fingerprint

Polyols
Cell death
Cytotoxicity
Silver
Sugars
Nanoparticles
Assays
Cells
Breast Neoplasms
Experiments
Neoplasms
Lethal Dose 50
soybean lectin
Breast
Cell Death
Neoplasm Metastasis

Cite this

@article{5a384a03185145d09329ec6256326d93,
title = "Soybean agglutinin-conjugated silver nanoparticles nanocarriers in the treatment of breast cancer cells",
abstract = "{\circledC} 2016 Taylor & Francis. Silver nanoparticles (AgNPs) induce diverse cell-death mechanisms, similar to those promoted by anticancer chemotherapeutics; however, they have not been tested in vivo because their action is not limited to cancer cells. Therefore, in vivo evaluations of their effectiveness should be developed with targeting systems. Breast cancer shows changes in the sugar expression patterns on cell surfaces, related to cancer progression and metastases; those changes have been identified previously by the specific binding of soybean agglutinin (SBA). Here is proposed the use of SBA to target the AgNP activity in breast cancer. For that, the present work reports the synthesis of AgNPs (3.89 ± 0.90 nm) through the polyol method, the generation of AgNP nanocarriers, and the bioconjugation protocol of the nanocarrier with SBA. The free AgNPs, the AgNP nanocarriers, and the SBA-bioconjugated AgNP nanocarriers were tested for cytotoxicity in breast cancerous (MDA-MB-231and MCF7) and non cancerous (MCF 10A) cells, using the MTT assay. AgNPs demonstrated cytotoxic activity in vitro, the non cancerous cells (MCF 10A) being more sensible than the cancerous cells (MDA-MB-231 and MCF7) showing LD50 values of 128, 205, and 319 M Ag, respectively; the nanoencapsulation decreased the cytotoxic effect of AgNPs in non cancerous cells, maintaining or increasing the effect on the cancer-derived cells, whereas the SBA-bioconjugation allowed AgNP cytotoxic activity with a similar behavior to the nanocarriers. Future experiments need to be developed to evaluate the targeting effect of the SBA-bioconjugated AgNP nanocarriers to study their functionality in vivo.",
author = "Pimentel, {Rocio Guadalupe Casa{\~n}as} and {Robles Botero}, Viviana and Mart{\'i}nez, {Eduardo San Mart{\'i}n} and {G{\'o}mez Garc{\'i}a}, Consuelo and Hinestroza, {Juan Paulo}",
year = "2016",
month = "2",
day = "11",
doi = "10.1080/09205063.2015.1116892",
language = "American English",
pages = "218--234",
journal = "Journal of Biomaterials Science, Polymer Edition",
issn = "0920-5063",
publisher = "Taylor and Francis Ltd.",

}

Soybean agglutinin-conjugated silver nanoparticles nanocarriers in the treatment of breast cancer cells. / Pimentel, Rocio Guadalupe Casañas; Robles Botero, Viviana; Martínez, Eduardo San Martín; Gómez García, Consuelo; Hinestroza, Juan Paulo.

In: Journal of Biomaterials Science, Polymer Edition, 11.02.2016, p. 218-234.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Soybean agglutinin-conjugated silver nanoparticles nanocarriers in the treatment of breast cancer cells

AU - Pimentel, Rocio Guadalupe Casañas

AU - Robles Botero, Viviana

AU - Martínez, Eduardo San Martín

AU - Gómez García, Consuelo

AU - Hinestroza, Juan Paulo

PY - 2016/2/11

Y1 - 2016/2/11

N2 - © 2016 Taylor & Francis. Silver nanoparticles (AgNPs) induce diverse cell-death mechanisms, similar to those promoted by anticancer chemotherapeutics; however, they have not been tested in vivo because their action is not limited to cancer cells. Therefore, in vivo evaluations of their effectiveness should be developed with targeting systems. Breast cancer shows changes in the sugar expression patterns on cell surfaces, related to cancer progression and metastases; those changes have been identified previously by the specific binding of soybean agglutinin (SBA). Here is proposed the use of SBA to target the AgNP activity in breast cancer. For that, the present work reports the synthesis of AgNPs (3.89 ± 0.90 nm) through the polyol method, the generation of AgNP nanocarriers, and the bioconjugation protocol of the nanocarrier with SBA. The free AgNPs, the AgNP nanocarriers, and the SBA-bioconjugated AgNP nanocarriers were tested for cytotoxicity in breast cancerous (MDA-MB-231and MCF7) and non cancerous (MCF 10A) cells, using the MTT assay. AgNPs demonstrated cytotoxic activity in vitro, the non cancerous cells (MCF 10A) being more sensible than the cancerous cells (MDA-MB-231 and MCF7) showing LD50 values of 128, 205, and 319 M Ag, respectively; the nanoencapsulation decreased the cytotoxic effect of AgNPs in non cancerous cells, maintaining or increasing the effect on the cancer-derived cells, whereas the SBA-bioconjugation allowed AgNP cytotoxic activity with a similar behavior to the nanocarriers. Future experiments need to be developed to evaluate the targeting effect of the SBA-bioconjugated AgNP nanocarriers to study their functionality in vivo.

AB - © 2016 Taylor & Francis. Silver nanoparticles (AgNPs) induce diverse cell-death mechanisms, similar to those promoted by anticancer chemotherapeutics; however, they have not been tested in vivo because their action is not limited to cancer cells. Therefore, in vivo evaluations of their effectiveness should be developed with targeting systems. Breast cancer shows changes in the sugar expression patterns on cell surfaces, related to cancer progression and metastases; those changes have been identified previously by the specific binding of soybean agglutinin (SBA). Here is proposed the use of SBA to target the AgNP activity in breast cancer. For that, the present work reports the synthesis of AgNPs (3.89 ± 0.90 nm) through the polyol method, the generation of AgNP nanocarriers, and the bioconjugation protocol of the nanocarrier with SBA. The free AgNPs, the AgNP nanocarriers, and the SBA-bioconjugated AgNP nanocarriers were tested for cytotoxicity in breast cancerous (MDA-MB-231and MCF7) and non cancerous (MCF 10A) cells, using the MTT assay. AgNPs demonstrated cytotoxic activity in vitro, the non cancerous cells (MCF 10A) being more sensible than the cancerous cells (MDA-MB-231 and MCF7) showing LD50 values of 128, 205, and 319 M Ag, respectively; the nanoencapsulation decreased the cytotoxic effect of AgNPs in non cancerous cells, maintaining or increasing the effect on the cancer-derived cells, whereas the SBA-bioconjugation allowed AgNP cytotoxic activity with a similar behavior to the nanocarriers. Future experiments need to be developed to evaluate the targeting effect of the SBA-bioconjugated AgNP nanocarriers to study their functionality in vivo.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84954360492&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84954360492&origin=inward

U2 - 10.1080/09205063.2015.1116892

DO - 10.1080/09205063.2015.1116892

M3 - Article

SP - 218

EP - 234

JO - Journal of Biomaterials Science, Polymer Edition

JF - Journal of Biomaterials Science, Polymer Edition

SN - 0920-5063

ER -